Please assess the completion status of the following clinical trial:

Trial Title: Oral Anticoagulation in Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* inclusion in the trial with clinicaltrials.gov identifier NCT02610933~* signed informed consent for this extension trial~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
- rivaroxaban (Type: EXPERIMENTAL): Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
- rivaroxaban + K2 (Type: EXPERIMENTAL): Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements

Based on this trial design, predict the completion outcome and termination type (if applicable).